Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb;28(1):145-150.
doi: 10.1007/s13365-021-01028-1. Epub 2021 Dec 7.

Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases

Sarah Darcy  1 , Michael Alexander  2 , Allan McCarthy #  3 , Seán O'Dowd #  3
Affiliations
Case Reports

Pembrolizumab treatment of inflammatory progressive multifocal leukoencephalopathy: a report of two cases

Sarah Darcy et al. J Neurovirol. 2022 Feb.

Abstract

Progressive multifocal leukoencephalopathy (PML) is a rare but devastating neurological disease caused by reactivation of the JC virus in susceptible individuals. The illness has classically been associated with the human immunodeficiency virus (HIV) and multiple sclerosis (MS) patients who are treated with natalizumab. It is also associated with haematological malignancies, organ transplantation, autoimmune disease and immunodeficiency. Aside from natalizumab, a range of other immunomodulators including obinutuzumab and rituximab have been associated with PML. The nature of these associations is unclear due to the overall low incidence of PML associated with these drugs and the fact that most patients will have other confounding risk factors for developing the disease. There is no known effective treatment available for PML in the non-HIV, non-MS cohort. Recent case studies and series have proposed that pembrolizumab, an anti-PD-1 immune checkpoint inhibitor, may be a potentially efficacious option for these patients. We present two cases of non-HIV, non-MS patients with PML who were treated with pembrolizumab with little clinical benefit. The literature surrounding pembrolizumab use in PML is discussed, with a focus on potential indicators of successful outcomes for patients who receive this therapy.

Keywords: Anti-CD20 monoclonal antibodies; Immune checkpoint inhibitors; JC virus; Progressive multifocal leukoencephalopathy.

PubMed Disclaimer

References

    1. Alleg M, Solis M, Baloglu S et al (2020) Progressive multifocal leukoencephalopathy: MRI findings in HIV-infected patients are closer to rituximab- than natalizumab-associated PML. Eur Radiol 1–12. https://doi.org/10.1007/s00330-020-07362-y . [published online ahead of print, 2020 Nov 6]
    1. Antinori A, Ammassari A, Giancola ML, Cingolani A, Grisetti S, Murri R, Alba L, Ciancio B, Soldani F, Larussa D, Ippolito G, De Luca A (2001) Epidemiology and prognosis of AIDS-associated progressive multifocal leukoencephalopathy in the HAART era. J Neurovirol 7(4):323–328. https://doi.org/10.1080/13550280152537184
    1. Boddy C, Bennett C, Norris L, Georgantopoulos P, Luo S, Carson K (2014) Rituximab-associated progressive multifocal leukoencephalopathy (PML) in HIV-negative patients: an updated report of 231 confirmed cases from the southern network on adverse reactions (SONAR)/Washington University Collaboration (2000–2012). Blood 124(21):4456–4456. https://doi.org/10.1182/blood.V124.21.4456.4456 - DOI
    1. Bohra C, Sokol L, Dalia S (2017) Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review. Cancer Control 24(4):1073274817729901. https://doi.org/10.1177/1073274817729901 - DOI - PubMed - PMC
    1. Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB (2018) Progressive multifocal leukoencephalopathy in rituximab treated rheumatic diseases: a rare event. J Neurovirol 24(3):323–331. https://doi.org/10.1007/s13365-018-0615-7 . [published correction appears in J Neurovirol. 2018 Apr 10]

Publication types

MeSH terms

LinkOut - more resources